SEC Contract Filing

Filing Date: 2020-10-29

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ptct-20200930ex101c45b08.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge 9.7.0.58--><!--Created on: 10/29/2020 08:16:56 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.54%;padding-right:6.21%;position:relative;"><div style="min-height:80pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.31;text-align:center;margin:3.79pt 78.75pt 0pt 0pt;"><b style="font-size:14pt;font-weight:bold;">Collaborative Research Agreement Amendment 5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-indent:0.05pt;margin:11.55pt 55.5pt 0pt 46.45pt;">This Amendment 5 is made and entered into as of the last date signed below (the &quot;Amendment 5 Effective Date&quot;) to that certain Collaborative Research Agreement dated September 30, 2015 (as amended, the &quot;Agreement&quot;) by and between National Taiwan University at No. 1, Sec. 4, Roosevelt Road, Taipei, 10617 Taiwan (R.O.C) (hereinafter &quot;NTU&quot;) and PTC Therapeutics GT, Inc. (formerly Agilis Biotherapeutics), a Delaware corporation duly organized under law and having an address at 6 Kimball Lane, Suite 320, Lynnfield, Massachusetts, 01940 USA<font style="letter-spacing:-1.05pt;"> </font>(hereinafter &quot;COMPANY&quot;). Capitalized terms herein shall have the meaning ascribed to them in the<font style="letter-spacing:-1.55pt;"> </font>Agreement. To the extent of any conflict with the prior amendments to the Agreement, this Amendment 5 supersedes the prior amendments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-indent:0.05pt;margin:0pt 50.7pt 0pt 46.75pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">WHEREAS</i>, the COMPANY and NTU previously amended the agreement via Amendments 1 through 4. In Amendment 4, the COMPANY and NTU agreed to a three year extension of the Term from October 1, 2017 to September<font style="letter-spacing:1.55pt;"> </font>30,<font style="letter-spacing:-0.35pt;"> </font><font style="white-space:pre-wrap;">2020; extension and expansion of the AADC-010 and the 011 Phase IIb protocol studies and related research; and corresponding increases in the Budget. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-indent:0.05pt;margin:0pt 50.7pt 0pt 46.75pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-indent:0.05pt;margin:0pt 50.7pt 0pt 46.75pt;"><i style="font-style:italic;text-decoration:underline;text-decoration-color:#000000;">NOW, THEREFORE</i>, the COMPANY and NTU wish to further amend the Agreement as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-indent:0.05pt;margin:0pt 50.7pt 0pt 46.75pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-indent:0.05pt;margin:0pt 50.7pt 0pt 46.75pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:46.8pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;line-height:1.26;text-align:left;text-decoration:underline;text-decoration-color:#000000;">No-Cost Extension of the Term and the</b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;line-height:1.26;text-align:left;text-decoration:underline;text-decoration-color:#000000;"> </b><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;line-height:1.26;text-align:left;text-decoration:underline;text-decoration-color:#000000;">AADC-010 and 011 Phase IIb protocol studies</b><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.26;text-align:left;white-space:pre-wrap;">: </font></td><td style="width:50.7pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 50.7pt 0pt 64.8pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 50.7pt 0pt 64.8pt;">The parties hereby agree that the Term and the duration of the AADC-010 and the 011 Phase IIb protocol studies are further extended, from September 30, 2020 to December 31, 2020, at no additional cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 50.7pt 0pt 64.8pt;"><font style="margin-left:0pt;margin-righ